Try GOLD - Free
India cuts China bulk-drug reliance
Mint Ahmedabad
|March 17, 2025
Bulk drugs accounted for 63% of the total pharmaceutical imports in the country during FY 2018-19
Indian companies have started manufacturing important bulk drugs or active pharmaceutical ingredients (APIs) under the government's production linked incentive (PLI) scheme.
The production of Penicillin G and Clavulanic Acid began in October last year. Other APIs already in production include Atorvastatin, Sulfadiazine, Telmisartan, Olmesartan, Para Amino Phenol (raw material for paracetamol) and Oxcarbazepine.
The development is set to make India less reliant on China for imports of raw material used by the pharmaceutical industry.
These bulk drugs are largely used as antibiotics and to manage non-communicable diseases such as cardiovascular diseases, chronic respiratory diseases, and diabetes.
This story is from the March 17, 2025 edition of Mint Ahmedabad.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Mint Ahmedabad
Mint Ahmedabad
Maruti ramps up its green logistics infra
The country’s largest carmaker Maruti Suzuki India Ltd on Wednesday said it has committed ₹1,372 crore towards dedicated green logistics infrastructure, as it aims to increase share of rail-based vehicle dispatches to 35% by 2030-31.
1 min
May 14, 2026
Mint Ahmedabad
‘Investors are in a wait-and-watch mode’
Despite the ongoing market volatility and geopolitical uncertainties, India remains firmly at the centre of global emerging market allocations, said Rahul Malhotra, region head of emerging markets and member of the global wealth management committee at Julius Baer Bank.
2 mins
May 14, 2026
Mint Ahmedabad
Tokenize gold: it could help unlock idle capital
Gold’s appeal in India can't be contested. To reduce imports and put local hoards to economic use, tokenized gold trading on RBI’s e-rupee platform may be an idea whose time has come
2 mins
May 14, 2026
Mint Ahmedabad
Rupee may slide to 96-98 by December-end amid oil shock
The Indian rupee is sliding from one record low to another, but economists say assigning a precise trajectory to the currency has become increasingly difficult amid the US-Iran war and the resultant crude oil shock.
2 mins
May 14, 2026
Mint Ahmedabad
Language was no barrier for Zubeen
Zubeen Garg wasn't just an Assamese singer but a genuinely multilingual artist capable of working across India’s complex linguistic landscape
4 mins
May 14, 2026
Mint Ahmedabad
In Street chaos, a tiny set of stocks sees big returns
Beneath the gloom gripping Indian equities, a quiet rally is reshaping parts of the market. Even as foreign investors pull money out, crude prices climb and benchmark indices struggle, a narrow band of companies tied to infrastructure, industrials and commodities is emerging as a winner.
2 mins
May 14, 2026
Mint Ahmedabad
Brown-Forman taps India spirits boom
As Indian consumers move beyond single-brand loyalty and expand their drinking “repertoire” across categories, Brown-Forman, the maker of Jack Daniel's, is banking on India’s premium spirits boom to sustain strong double-digit growth, even as competition intensifies across imported whiskey segments and supply chain risks persist.
1 mins
May 14, 2026
Mint Ahmedabad
Nod for user fee at Noida airport, to bill 4x more than Delhi
India’s airport regulator has allowed Noida International Airport to charge domestic passengers user development fees (UDF) that are almost four times the tariff levied at the capital’s Indira Gandhi International Airport (IGIA).
1 mins
May 14, 2026
Mint Ahmedabad
Govt weighs a ban on paraquat, carbosulfan
The Centre is considering a nationwide ban on crop-protection chemicals paraquat and carbosulfan after Telangana and Odisha imposed restrictions on their use, two people familiar with the matter told Mint.
1 min
May 14, 2026
Mint Ahmedabad
Dixon’s stumble is a test for electronics manufacturers
Dixon Technologies’ consolidated revenues rose by just 2% year-on-year in the March quarter (Q4FY26) to ₹10,511 crore, the same as Q3’s growth rate.
1 mins
May 14, 2026
Listen
Translate
Change font size